Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer: Case report

European Journal of Cancer Care

Volumn 17, Issue 3, 2008, Pages 306-311

  Cheng, K K F ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Children; Hepatic enzyme; Methotrexate; Nausea vomiting; Neutropenia; Oral mucositis

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; METHOTREXATE;

ADOLESCENT; ARTICLE; BLOOD; BONE TUMOR; CHEMICALLY INDUCED DISORDER; CHILD; COMPARATIVE STUDY; EPIDEMIOLOGY; FEMALE; HUMAN; LIVER DISEASE; LYMPHATIC LEUKEMIA; MALE; NAUSEA; NEUTROPENIA; OSTEOSARCOMA; STOMATITIS; VOMITING;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; CHILD; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LIVER DISEASES; MALE; METHOTREXATE; NAUSEA; NEUTROPENIA; OSTEOSARCOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STOMATITIS; VOMITING;

EID: 42449136257     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2007.00843.x     Document Type: Article

References (24)

1. Barasch A. Peterson D.E. (2003) Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncology 39, 91 100.
2. Berger A.M. Eilers J. (1998) Factors influencing oral cavity status during high-dose antineoplastic therapy: a secondary data analysis. Oncology Nursing Forum 25, 1623 1626.
3. Blatt J., Howrie D.L. Wollman M.R. (1993) Toxicity following concurrent intrathecal and moderate-dose intravenous methotrexate. Leukemia 7, 1734 1737.
4. Borbasi S., Cameron K., Quested B., Olver I., To B. Evans D. (2002) More than a sore mouth: patients' experience of oral mucositis. Oncology Nursing Forum 29, 1051 1057.
5. Cheng K.K.F. Chang A.M. (2004) Palliation of oral mucositis symptoms in pediatric patients treated with cancer chemotherapy. Cancer Nursing 26, 433 441.
6. Cheng K.K.F., Chang A.M. Yuen M.P. (2004) Prevention of chemotherapy-induced oral mucositis in pediatric patients: a randomized crossover trial comparing two protocols of oral care. European Journal of Cancer 20, 1208 1216.
7. Cheng K.K.F., Molassiotis A., Chang A.M., Wai W.C. Cheung S.C. (2001) Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in pediatric cancer patients. European Journal of Cancer 37, 2056 2063.
8. Dodd M.J., Miaskowski C., Shiba G.H., Dibble S.L., Greenspan D., MacPhail L., Paul S.M. Larson P. (1999) Risk factors for chemotherapy-induced oral mucositis: dental appliances, oral hygiene, previous oral lesions, and history smoking. Cancer Investigation 17, 278 284.
9. Dreizen S. (1990) Description and incidence of oral complications. NCI Monographs 9, 11 15.
10. Exadaktylos P., Reiss T., Schobess R., Hommann M., Hohne S. Beck A. (1994) Acute hepatotoxicity with intermediate-dose methotrexate in children with leukemia and non-hodgkin's lymphoma. Klinische Pädiatrie 206, 315 318.
11. Fayle S.A. Curzon M.E.J. (1991) Oral complications in pediatric oncology patients. Journal of Periodontology 13, 289 295.
12. Ishii E., Yamada S., Higuchi S., Honjo T., Lgarashi H., Kanemitsu S., Kai T. Ueda K. (1989) Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphobastic leukemia. Medical and Pediatric Oncology 17, 429 432.
13. Lockhart P. Sonis S. (1979) Relationship of oral complications to peripheral blood leukocyte and platelet count in patients receiving cancer chemotherapy. Oral Surgery, Oral Medicine, Oral Pathology 48, 21 28.
14. Loprinzi C.L., Gastineau D.A. Foote R.L. (1995) Oral complications. In : Clinical Oncology (eds Abeloff, M.D., Armitage, J.O., Lichter, A.S. Niederhuber, J.E.), pp. 741 754. Churchhill Livingstone, New York, NY, USA.
15. McCarthy G.M., Awde J.D., Ghandi H., Vincet M. Kocha W.I. (1998) Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncology 34, 489 490.
16. Oliff A., Bleyer A. Poplack D.G. (1979) Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemotherapy and Pharmacology 2, 225 226.
17. Quinn E., Kenneth H. Kenneth D. (1991) Methotrexate and histologic hepatic abnormalities: a meta analysis. The American Journal of Medicine 90, 711 716.
18. Rask C., Albertioni F., Schroeder H. Peterson C. (1996) Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate. Pediatric Hematology and Oncology 13, 359 367.
19. Rask C., Albertioni F., Bentzen S.M., Schroeder H. Peterson C. (1998) Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia. Acta Oncologica 37, 277 284.
20. Relling M.V., Fairclough D. Ayers D. (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. Journal of Clinical Oncology 12, 1667 1672.
21. Sonis S.T. (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncology 34, 39 43.
22. Sonis S.T., Elting L.S., Keefe D., Peterson D.E., Schubert M., Hauer-Jensen M., Bekele B.N., Raber-Durlacher J., Donnelly J.P. Rubenstein E.B. (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100, 1995 2005.
23. Walco G.A., Sterling C.M., Conte P.M. Engel R.G. (1999) Empirically supported treatments in pediatric psychology: disease-related pain. Society of Pediatric Psychology 24, 155 167.
24. Wardley A.M., Jayson G.C., Swidnell R., Morgenstern G.R., Chang J., Bloor R., Fraser C.J. Scarffe J.H. (2000) Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. British Journal of Haematology 110, 292 299.